Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPICOL: Nivolumab + Ipilimumab in dMMR/MSI mCRC
NCT03350126Phase 2Active, not recruiting
- Sponsor
- GERCOR
- Start
- Dec 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in colorectal cancer (CRC), sponsored by GERCOR. Started Dec 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03350126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350126.